encorafenib,Binimetinib,Cetuximab
pfizer,ono pharmacueticals,pierre fabre,eli lilly
[]
 it should have been randomised, it should have built in crossover. and we can debate if there should be another doublet arm. given the u.k. drops the binimetanib.
Junior Doctor at Southampton. Tweets my own. No FCOI.